As an oncogene, JPX is significantly upregulated in NSCLC tissues and is associated with poor prognosis; JPX upregulates cyclin D2 expression in the ceRNA mechanism by interacting with miR-145-5p, which stimulates NSCLC development and progression [39]. This evidence concerns the gene JPX and non-small cell lung carcinoma.